Pyxis Oncology (PYXS) AI Stock Analysis

• Market Cap: $65.29M
• Dividend Yield: N/A
• Average Volume (3M): 605.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: 30.51%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.29
• Shares Outstanding: 61,590,416
• 10 Day Avg. Volume: 462,447
• 30 Day Avg. Volume: 605,412
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4.62
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.25
• Price Target Upside: 583.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Pyxis Oncology's overall score reflects its financial challenges and weak technical indicators. The strategic focus on its lead product candidate offers potential growth, but profitability and valuation concerns weigh heavily. Significant liabilities and cash flow issues present risks, while the recent corporate strategy offers a positive outlook for future developments.

Positive Factors

Clinical Trials

Pyxis's streamlined focus on executing micvotabart pelidotin’s Ph 1 trial in squamous cell carcinoma of the head & neck is expected to maximize clinical investment and potential return.

Strategic Partnerships

The Company has a clinical trial collaboration agreement with Merck for a combination therapy with Keytruda, targeting head and neck squamous cell carcinoma patients.

Negative Factors

Financial Performance

For FY24, the company reported a net loss of $1.32 per share, compared to the consensus estimated net loss of $1.09 per share.

Market Challenges

Short interest stands at 16.6% of the float, indicating a significant portion of investors are betting against the stock.

Pyxis Oncology Business Overview & Revenue Model

Company Description

Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.

How the Company Makes Money

Pyxis Oncology generates revenue through a combination of research and development collaborations, licensing agreements, and potential milestone payments from strategic partnerships with other pharmaceutical companies. The company's business model is largely reliant on advancing its pipeline of oncology therapeutics through clinical trials, securing regulatory approvals, and ultimately commercializing these products either independently or through collaborators. Revenue streams may also include upfront payments and royalties from licensing its technologies and products to other companies in the pharmaceutical industry. The success of Pyxis Oncology's revenue model depends on its ability to successfully develop and market its therapeutic candidates, as well as forming beneficial partnerships that enhance its product offerings and market reach.

Pyxis Oncology Financial Statement Overview

Summary

Pyxis Oncology is in a development phase, showing initial revenue generation but facing challenges in profitability and cash flow. Despite a strong equity position, high debt-to-equity ratio and ongoing net losses present risks.

Income Statement

Pyxis Oncology has shown some positive revenue generation in the TTM, marking its first reported revenue of $19.57 million, which is a significant improvement from previous periods of zero revenue. However, the company struggles with profitability as indicated by negative net profit margin, EBIT margin, and EBITDA margin. The TTM net income of -$57.36 million reflects ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reflects a relatively strong equity position with stockholders' equity at $153.68 million in TTM. However, the company has a high debt-to-equity ratio, given a total debt of $20.54 million. Despite this, the equity ratio of 78.68% indicates a solid capital structure. The return on equity is negative, reflecting the ongoing net losses.

Cash Flow

Operating cash flow remains negative at -$53.57 million in the TTM, indicating challenges in cash generation from core operations. Free cash flow has improved slightly but remains negative. The operating cash flow to net income ratio is close to 1, reflecting similar trends in cash outflows and net income losses.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
19.57M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
16.63M	-2.00M	-1.84M	-1.25M	-444.00K	0.00
	EBIT
-67.16M	-82.20M	-123.48M	-69.72M	-12.89M	-2.88M
	EBITDA
-64.05M	-78.49M	-122.77M	-69.07M	-12.43M	0.00
	Net Income Common Stockholders
-57.36M	-73.79M	-117.95M	-81.54M	-12.76M	-2.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.69M	119.30M	179.29M	274.74M	8.08M	19.69M
	Total Assets
0.00	173.73M	211.38M	280.02M	10.15M	19.81M
	Total Debt
0.00	21.33M	18.92M	165.00K	780.00K	15.00K
	Net Debt
19.69M	11.67M	-160.37M	-274.57M	-7.30M	-19.68M
	Total Liabilities
0.00	48.02M	50.55M	18.71M	25.80M	22.68M
	Stockholders Equity
19.07M	125.70M	160.82M	261.31M	-15.64M	-2.87M
Cash Flow		Free Cash Flow
-53.81M	-77.44M	-95.73M	-35.87M	-11.57M	-2.24M
	Operating Cash Flow
-53.57M	-70.71M	-89.33M	-35.33M	-10.08M	-2.24M
	Investing Cash Flow
-8.27M	-104.85M	-6.40M	-590.00K	-1.48M	0.00
	Financing Cash Flow
59.25M	5.93M	183.00K	304.04M	35.00K	21.95M

Pyxis Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Negative. The current price of 1.06 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.29, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.96 is Neutral, neither overbought nor oversold. The STOCH value of 11.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PYXS.

Pyxis Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
CABA	45 Neutral	$75.76M	―	-62.16%	―	―	-25.02%
PYXS	42 Neutral	$65.29M	―	-62.75%	―	―	30.51%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
KALA	42 Neutral	$36.85M	―	-430.96%	―	―	70.70%
NRIX	41 Neutral	$922.02M	―	-53.22%	―	-29.15%	-9.10%
BHVN	37 Underperform	$2.82B	―	-198.83%	―	―	-65.63%

Pyxis Oncology Corporate Events

Pyxis Oncology Highlights Strategic Focus on Lead Candidate

On March 24, 2025, Pyxis Oncology updated its corporate presentation, highlighting its focus on advancing its lead product candidate, micvotabart pelidotin, for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company is positioning itself as a differentiated ADC company with a strong cash runway and multiple clinical data catalysts expected in 2025 and 2026. This strategic focus aims to address significant unmet needs in the R/M HNSCC treatment landscape, potentially enhancing Pyxis Oncology’s position in the oncology sector.

Pyxis Oncology Announces CMO Resignation and New Trials

On March 18, 2025, Pyxis Oncology announced the resignation of Ken Kobayashi, M.D., as Chief Medical Officer, with Lara S. Sullivan, M.D., assuming the role alongside her current duties as President and CEO. The company also reported positive preliminary data from its Phase 1 trial of micvotabart pelidotin, receiving Fast Track Designation from the FDA for treating certain head and neck cancers, and initiated further clinical trials, including a combination study with Merck’s KEYTRUDA®. Pyxis Oncology has streamlined its operations, reducing its workforce by 20% to focus on advancing the MICVO clinical program, and expects its cash runway to extend into the second half of 2026.